MBX Biosciences, Inc. Common Stock
Financials
Valuation Metrics
MBX Biosciences, Inc. Common Stock's Market Cap is $2.59B. At end of 2025 it was $1.15B. Ranked #1783 of 3,118 in US market (top 57%), #639 of 1,474 on NASDAQ (top 43%), #110 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 42%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.59B | US#1,783/3,118 Sec#110/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-104M | US—/3,118 Sec—/265 |
| Total Assets | $436M | US#2,810/3,118 Sec#174/265 |
| Net Assets | $410M | US#2,347/3,118 Sec#129/265 |
| Employees | 63 | US#2,671/3,118 Sec#197/265 |
| Value | ||
| P/B | 6.32x | US#2,402/3,118 Sec#163/265 |
| FCF Yield | -3.29% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -25.47% | US#2,527/3,118 Sec#107/265 |
| ROA | -23.93% | US#2,831/3,118 Sec#141/265 |
| Financial Health | ||
| Debt Ratio | 6.44% | US#55/3,118 Sec#26/265 |
| Total Debt | $3M | US#2,918/3,118 Sec#224/265 |
| FCF | $-85M | US#2,609/3,118 Sec#135/265 |
| Cash | $54M | US#2,545/3,118 Sec#221/265 |
| Current Ratio | 18.08x | US#126/3,118 Sec#32/265 |
| Performance | ||
| 1Y Return | 147.45% | US#55/3,118 Sec#18/265 |
| 1M Return | -7.13% | US#2,171/3,118 Sec#151/265 |
| From 52W High | -25.19% | US#1,627/3,118 Sec#97/265 |
| 1Y MDD | -35.51% | US#1,676/3,118 Sec#92/265 |
| Trading | ||
| Volume | 277,128 shares | US#1,840/3,118 Sec#181/265 |
| Trading Value | $15M | US#1,509/3,118 Sec#104/265 |
| Per Share | ||
| EPS | $-2.19 | US—/3,118 Sec—/265 |
| BPS | $8.60 | US#1,936/3,118 Sec#80/265 |
Company Info
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.